Alzamend Neuro presents Phase 1/2A AL001 lithium brain-imaging data at ISMRT on Sept. 29, 2026

Alzamend Neuro, Inc.

Dr. Ovidiu C. Andronesi presented Phase 1/2A results at the ISMRT Workshop on Sept. 29, 2026, covering 30 participants: 6 each healthy, bipolar, major depression, Alzheimer's, and PTSD.
AL001 is a lithium salicylate/L-proline co-crystal; trial NCT06921590 used 7T Terra.X MRI and compared AL001 with Li2CO3 in a randomized crossover.
Brain Li concentration trended higher after AL001 (geometric mean 4020.64 ng/g, 64% CV) vs Li2CO3 (3476.94 ng/g, 57% CV), but differences were not statistically significant.
Non-compartmental PK AUC trended higher for AL001 (geometric mean 62230 h*ng/g, 26% CV) vs Li2CO3 (59715 h*ng/g, 25% CV); two-compartment modeling showed higher white-matter K1.
92% of lithium images were scored excellent to adequate, with Gwet's agreement coefficient 0.73 (95% CI 0.66-0.80).

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.